Tjadine M Holling
Overview
Explore the profile of Tjadine M Holling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
430
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Eggermond M, Boom D, Klous P, Schooten E, Marquez V, Wierda R, et al.
Biochem Pharmacol
. 2011 Jun;
82(10):1430-7.
PMID: 21664896
In humans, T-cells accomplish expression of MHC-II molecules through induction of CIITA upon activation. Here we show that CIITA promoter accessibility in T-cells is epigenetically regulated. In unstimulated T-cells, CIITA-PIII...
2.
Holling T, Bergevoet M, Wierda R, van Eggermond M, van den Elsen P
Ann N Y Acad Sci
. 2009 Sep;
1173:538-44.
PMID: 19758196
The transcriptional regulation of the major histocompatibility complex class (MHC) Ib gene HLA-G differs from the classical MHC class I genes. The cis-acting regulatory elements typical for classical MHC class...
3.
Holling T, Bergevoet M, Wilson L, van Eggermond M, Schooten E, Steenbergen R, et al.
J Immunol
. 2007 Oct;
179(8):5317-25.
PMID: 17911618
We investigated the contribution of epigenetic mechanisms in MHC2TA transcriptional silencing in uveal melanoma. Although no correlation was observed between impaired CIITA transcript levels after IFN-gamma induction and DNA methylation...
4.
van der Stoep N, Quinten E, Alblas G, Plancke A, van Eggermond M, Holling T, et al.
Mol Immunol
. 2006 Oct;
44(8):2036-46.
PMID: 17067677
Cell lines established from tumor tissue of cutaneous melanoma biopsies often display constitutive and IFNgamma-inducible expression of MHC class II molecules. The expression of MHC class II molecules in melanoma...
5.
Holling T, van Eggermond M, Jager M, van den Elsen P
Biochem Pharmacol
. 2006 Aug;
72(11):1570-6.
PMID: 16879803
Lack of expression of major histocompatibility complex (MHC) molecules of both classes is frequently noted on tumour cells . It is thought that in this way tumour cells escape immunosurveillance....
6.
Penning L, Piek C, Eib D, Schipper R, Holling T, Martens G
Anticancer Res
. 2006 Feb;
26(1A):339-46.
PMID: 16475715
Tomoregulin-1, a type-I transmembrane protein with two follistatin modules, a unique epidermal growth factor (EGF) domain and a short, highly conserved cytoplasmic tail, was studied. A number of hematopoietic cell...
7.
Schooten E, Klous P, van den Elsen P, Holling T
Immunogenetics
. 2005 Oct;
57(10):795-9.
PMID: 16235089
In contrast to activated human T cells, activated mouse T cells fail to express MHC class II molecules (MHC-II) at their cell surface. This is because mouse T cells hardly...
8.
Holling T, van der Stoep N, van den Elsen P
Biochem Pharmacol
. 2004 Aug;
68(6):1209-13.
PMID: 15313418
No abstract available.
9.
Holling T, Schooten E, van den Elsen P
Hum Immunol
. 2004 May;
65(4):282-90.
PMID: 15120183
The main function of major histocompatibility complex (MHC) class II molecules is to present processed antigens, which are derived primarily from exogenous sources, to CD4(+) T-lymphocytes. MHC class II molecules...
10.
van den Elsen P, Holling T, Kuipers H, van der Stoep N
Curr Opin Immunol
. 2004 Jan;
16(1):67-75.
PMID: 14734112
MHC class I and class II molecules play essential roles in the adaptive immune response by virtue of their ability to present peptides to T lymphocytes. Given their central role...